Measuring quality of life in multiple system atrophy

Anette Schrag, Caroline Selai, Christopher Mathias, Phillip Anson Low, Jeremy Hobart, Niall Quinn

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Introduction Multiple system atrophy (MSA) is a rare, progressive, neurodegenerative disease and a form of atypical parkinsonism. It has a prevalence of about 2 to 5 per 100,000 and has a considerable impact on patient outcomes, including reduced life expectancy, increased disability, and lower health-related quality of life (HRQoL). Average age of onset is about 54 years, and mean survival from the onset of symptoms is around 5 to 9 years. MSA often presents with features similar to those of Parkinson's disease (PD) in its early stages and consequently may be difficult to diagnose correctly. As a result, many patients may not receive appropriate treatment for their condition. However, despite the intial similarities, MSA has a wider range of symptoms and a differing and more aggressive disease progression and is poorly responsive to treatments commonly associated with PD, such as levopoda. Some evidence suggests that rates of depression are high in patients diagnosed with MSA. Currently, no treatment consistently benefits patients, resulting in increasing dependency on the patient's family and other caregivers, which in turn can have consequences for their HRQoL. MSA has two different subtypes. MSA-P is so called because of the predominance of parkinsonism symptoms, whereas MSA-C is identified by a predominance of cerebellar dysfunction. At present, few direct studies have evaluated HRQoL for patients with a diagnosis of MSA. Although Parkinson's disease has been the focus for a number of studies in the 1990s/2000s, very little research has been undertaken to study other forms of parkinsonism such as MSA. This is unfortunate because, although superficial similarities between the conditions have been noted, the more aggressive nature of MSA requires its own body of evidence to better study patients' outcomes, HRQoL, and health needs.

Original languageEnglish (US)
Title of host publicationQuality of Life Measurement in Neurodegenerative and Related Conditions
PublisherCambridge University Press
Pages60-70
Number of pages11
ISBN (Print)9780511975363, 9780521829014
DOIs
StatePublished - Jan 1 2011

Fingerprint

Multiple System Atrophy
Quality of Life
Parkinsonian Disorders
Parkinson Disease
Cerebellar Diseases
Life Expectancy
Age of Onset
Neurodegenerative Diseases
Caregivers
Disease Progression
Therapeutics
Outcome Assessment (Health Care)

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Schrag, A., Selai, C., Mathias, C., Low, P. A., Hobart, J., & Quinn, N. (2011). Measuring quality of life in multiple system atrophy. In Quality of Life Measurement in Neurodegenerative and Related Conditions (pp. 60-70). Cambridge University Press. https://doi.org/10.1017/CBO9780511975363.007

Measuring quality of life in multiple system atrophy. / Schrag, Anette; Selai, Caroline; Mathias, Christopher; Low, Phillip Anson; Hobart, Jeremy; Quinn, Niall.

Quality of Life Measurement in Neurodegenerative and Related Conditions. Cambridge University Press, 2011. p. 60-70.

Research output: Chapter in Book/Report/Conference proceedingChapter

Schrag, A, Selai, C, Mathias, C, Low, PA, Hobart, J & Quinn, N 2011, Measuring quality of life in multiple system atrophy. in Quality of Life Measurement in Neurodegenerative and Related Conditions. Cambridge University Press, pp. 60-70. https://doi.org/10.1017/CBO9780511975363.007
Schrag A, Selai C, Mathias C, Low PA, Hobart J, Quinn N. Measuring quality of life in multiple system atrophy. In Quality of Life Measurement in Neurodegenerative and Related Conditions. Cambridge University Press. 2011. p. 60-70 https://doi.org/10.1017/CBO9780511975363.007
Schrag, Anette ; Selai, Caroline ; Mathias, Christopher ; Low, Phillip Anson ; Hobart, Jeremy ; Quinn, Niall. / Measuring quality of life in multiple system atrophy. Quality of Life Measurement in Neurodegenerative and Related Conditions. Cambridge University Press, 2011. pp. 60-70
@inbook{9322c3d2cbaa4b1caff1b51bd4b11695,
title = "Measuring quality of life in multiple system atrophy",
abstract = "Introduction Multiple system atrophy (MSA) is a rare, progressive, neurodegenerative disease and a form of atypical parkinsonism. It has a prevalence of about 2 to 5 per 100,000 and has a considerable impact on patient outcomes, including reduced life expectancy, increased disability, and lower health-related quality of life (HRQoL). Average age of onset is about 54 years, and mean survival from the onset of symptoms is around 5 to 9 years. MSA often presents with features similar to those of Parkinson's disease (PD) in its early stages and consequently may be difficult to diagnose correctly. As a result, many patients may not receive appropriate treatment for their condition. However, despite the intial similarities, MSA has a wider range of symptoms and a differing and more aggressive disease progression and is poorly responsive to treatments commonly associated with PD, such as levopoda. Some evidence suggests that rates of depression are high in patients diagnosed with MSA. Currently, no treatment consistently benefits patients, resulting in increasing dependency on the patient's family and other caregivers, which in turn can have consequences for their HRQoL. MSA has two different subtypes. MSA-P is so called because of the predominance of parkinsonism symptoms, whereas MSA-C is identified by a predominance of cerebellar dysfunction. At present, few direct studies have evaluated HRQoL for patients with a diagnosis of MSA. Although Parkinson's disease has been the focus for a number of studies in the 1990s/2000s, very little research has been undertaken to study other forms of parkinsonism such as MSA. This is unfortunate because, although superficial similarities between the conditions have been noted, the more aggressive nature of MSA requires its own body of evidence to better study patients' outcomes, HRQoL, and health needs.",
author = "Anette Schrag and Caroline Selai and Christopher Mathias and Low, {Phillip Anson} and Jeremy Hobart and Niall Quinn",
year = "2011",
month = "1",
day = "1",
doi = "10.1017/CBO9780511975363.007",
language = "English (US)",
isbn = "9780511975363",
pages = "60--70",
booktitle = "Quality of Life Measurement in Neurodegenerative and Related Conditions",
publisher = "Cambridge University Press",

}

TY - CHAP

T1 - Measuring quality of life in multiple system atrophy

AU - Schrag, Anette

AU - Selai, Caroline

AU - Mathias, Christopher

AU - Low, Phillip Anson

AU - Hobart, Jeremy

AU - Quinn, Niall

PY - 2011/1/1

Y1 - 2011/1/1

N2 - Introduction Multiple system atrophy (MSA) is a rare, progressive, neurodegenerative disease and a form of atypical parkinsonism. It has a prevalence of about 2 to 5 per 100,000 and has a considerable impact on patient outcomes, including reduced life expectancy, increased disability, and lower health-related quality of life (HRQoL). Average age of onset is about 54 years, and mean survival from the onset of symptoms is around 5 to 9 years. MSA often presents with features similar to those of Parkinson's disease (PD) in its early stages and consequently may be difficult to diagnose correctly. As a result, many patients may not receive appropriate treatment for their condition. However, despite the intial similarities, MSA has a wider range of symptoms and a differing and more aggressive disease progression and is poorly responsive to treatments commonly associated with PD, such as levopoda. Some evidence suggests that rates of depression are high in patients diagnosed with MSA. Currently, no treatment consistently benefits patients, resulting in increasing dependency on the patient's family and other caregivers, which in turn can have consequences for their HRQoL. MSA has two different subtypes. MSA-P is so called because of the predominance of parkinsonism symptoms, whereas MSA-C is identified by a predominance of cerebellar dysfunction. At present, few direct studies have evaluated HRQoL for patients with a diagnosis of MSA. Although Parkinson's disease has been the focus for a number of studies in the 1990s/2000s, very little research has been undertaken to study other forms of parkinsonism such as MSA. This is unfortunate because, although superficial similarities between the conditions have been noted, the more aggressive nature of MSA requires its own body of evidence to better study patients' outcomes, HRQoL, and health needs.

AB - Introduction Multiple system atrophy (MSA) is a rare, progressive, neurodegenerative disease and a form of atypical parkinsonism. It has a prevalence of about 2 to 5 per 100,000 and has a considerable impact on patient outcomes, including reduced life expectancy, increased disability, and lower health-related quality of life (HRQoL). Average age of onset is about 54 years, and mean survival from the onset of symptoms is around 5 to 9 years. MSA often presents with features similar to those of Parkinson's disease (PD) in its early stages and consequently may be difficult to diagnose correctly. As a result, many patients may not receive appropriate treatment for their condition. However, despite the intial similarities, MSA has a wider range of symptoms and a differing and more aggressive disease progression and is poorly responsive to treatments commonly associated with PD, such as levopoda. Some evidence suggests that rates of depression are high in patients diagnosed with MSA. Currently, no treatment consistently benefits patients, resulting in increasing dependency on the patient's family and other caregivers, which in turn can have consequences for their HRQoL. MSA has two different subtypes. MSA-P is so called because of the predominance of parkinsonism symptoms, whereas MSA-C is identified by a predominance of cerebellar dysfunction. At present, few direct studies have evaluated HRQoL for patients with a diagnosis of MSA. Although Parkinson's disease has been the focus for a number of studies in the 1990s/2000s, very little research has been undertaken to study other forms of parkinsonism such as MSA. This is unfortunate because, although superficial similarities between the conditions have been noted, the more aggressive nature of MSA requires its own body of evidence to better study patients' outcomes, HRQoL, and health needs.

UR - http://www.scopus.com/inward/record.url?scp=84926080143&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84926080143&partnerID=8YFLogxK

U2 - 10.1017/CBO9780511975363.007

DO - 10.1017/CBO9780511975363.007

M3 - Chapter

AN - SCOPUS:84926080143

SN - 9780511975363

SN - 9780521829014

SP - 60

EP - 70

BT - Quality of Life Measurement in Neurodegenerative and Related Conditions

PB - Cambridge University Press

ER -